| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
(S)-4-Methyl-2-(methylamino)pentanoic acid hydrochloride does not have a specific therapeutic target. It is a synthetic intermediate, not a pharmacologically active compound. Its "target" in a research context is the specific site within a larger molecule where it is incorporated as a building block. By introducing a methylated amino acid residue, it can alter the properties of the final peptide or peptidomimetic, potentially affecting its interaction with biological targets like enzymes, receptors, or protein-protein interfaces. Its role is structural, not functional.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
The compound itself is a chemical intermediate and does not possess intrinsic in vitro biological activity. It is not tested in standard biological assays for effects on cell viability, proliferation, or signaling pathways. Its value is in its utility for synthesizing biologically active molecules. As a building block, it can be used to create peptide analogs with altered properties, such as increased resistance to enzymatic degradation, which are then studied for their biological activity. |
| ln Vivo |
As a synthetic intermediate, (S)-4-Methyl-2-(methylamino)pentanoic acid hydrochloride is not designed for in vivo use and has no reported intrinsic biological activity in animal models. It is not administered to animals for therapeutic or pharmacological testing. Its role is confined to the laboratory as a chemical precursor for the synthesis of more complex molecules that may eventually be studied in vivo.
|
| Enzyme Assay |
Cell-free assays are not applicable to (S)-4-Methyl-2-(methylamino)pentanoic acid hydrochloride. It is not a biologically active compound and is not used in enzyme/receptor binding studies. Its use is restricted to being a chemical reagent in synthetic organic chemistry. It may be used as a standard or reference material in analytical chemistry, but not in biochemical assays.
|
| Cell Assay |
No cell-based assays are performed with this compound. As a non-biological chemical intermediate, it is not used to treat cells for the purpose of studying a biological effect. Its application is in the test tube for chemical synthesis, not in the petri dish for biological experiments.
|
| Animal Protocol |
(S)-4-Methyl-2-(methylamino)pentanoic acid hydrochloride is not used in animal studies. It is a reagent for chemical synthesis and is not a drug candidate. No in vivo experiments are conducted with this compound to evaluate a therapeutic or toxicological effect.
|
| ADME/Pharmacokinetics |
This compound is not a drug and is not subject to pharmacokinetic evaluation. PK parameters (e.g., absorption, distribution, metabolism, excretion) are relevant only for compounds intended for systemic administration. As a synthetic intermediate, it has no such data.
|
| Toxicity/Toxicokinetics |
The toxicological profile of (S)-4-Methyl-2-(methylamino)pentanoic acid hydrochloride is not well characterized. Standard safety precautions for handling fine chemicals should be followed. It may cause skin, eye, and respiratory tract irritation. Use appropriate personal protective equipment and work in a well-ventilated area. Ingestion and inhalation should be avoided. In case of accidental exposure, seek medical advice.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
This compound is not a drug. It is a specialized chemical building block (methyl-L-leucine hydrochloride) for research and development. It is used in synthetic chemistry to introduce a methylated leucine residue into peptides or other molecules. This modification is a common strategy in medicinal chemistry to improve the metabolic stability, bioavailability, or target affinity of peptide-based drug candidates. It is not approved for any clinical use.
|
| Molecular Formula |
C7H16CLNO2
|
|---|---|
| Molecular Weight |
181.66
|
| Exact Mass |
181.086
|
| CAS # |
66866-69-1
|
| PubChem CID |
2777992
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
159-165 °C
|
| LogP |
1.898
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
11
|
| Complexity |
112
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)C[C@@H](C(=O)O)NC.Cl
|
| InChi Key |
QYFWCUVWMMTENJ-RGMNGODLSA-N
|
| InChi Code |
InChI=1S/C7H15NO2.ClH/c1-5(2)4-6(8-3)7(9)10;/h5-6,8H,4H2,1-3H3,(H,9,10);1H/t6-;/m0./s1
|
| Chemical Name |
(2S)-4-methyl-2-(methylamino)pentanoic acid;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5048 mL | 27.5239 mL | 55.0479 mL | |
| 5 mM | 1.1010 mL | 5.5048 mL | 11.0096 mL | |
| 10 mM | 0.5505 mL | 2.7524 mL | 5.5048 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
